Get started
Author

Shien Chow

Observed name: S. Chow
ORCID: 0000-0001-8609-1297
Observed ORCID: 0000-0001-8609-1297
OpenAlex ID: A5043227799
Mortality within 30days following systemic anti-cancer therapy, a review of all cases over a 4year period in a tertiary cancer centre
2014 · L. Khoja, A. McGurk, et al. · European Journal of Cancer · 37
High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome
2016 · S. Chow, V. Galvis, et al. · Journal for ImmunoTherapy of Cancer · 22
PDF
CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.
2021 · Rebecca Lee, Dominic G. Rothwell, et al. · Journal of Clinical Oncology · 11
High-dose Interleukin 2-induced Myocarditis: Can Myocardial Damage Reversibility be Assessed by Cardiac MRI?
2014 · Shien Chow, Laura Cove-Smith, et al. · Journal of Immunotherapy · 11
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies
2023 · Kyrillus S. Shohdy, Manon Pillai, et al. · eJHaem · 9
PDF
Managing IBD in patients with previous cancers
2022 · Sarah E Minnis-Lyons, Zara Aiken, et al. · Frontline Gastroenterology · 7
PDF
Oestrogen Receptor Positive Metastatic Eccrine Porocarcinoma: A Case Report and Review of Anti-Oestrogen Therapy in Rare Cancers
2024 · Anita J.M. Kalakonda, Abishek Mahajan, et al. · Case Reports in Oncology · 4
PDF
Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study
2022 · Jakub Lagan, Josephine H. Naish, et al. · Diagnostics · 4
PDF
Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis
2023 · Jonathan Heseltine, Jennifer Allison, et al. · Targeted Oncology · 3
10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).
2016 · Shien Chow, Manon Rhys Pillai, et al. · Journal of Clinical Oncology · 3
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
2024 · Nigel Fleeman, Rachel Houten, et al. · Health Technology Assessment · 2
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.
2020 · Sam Wong, Kellati Prasad, et al. · Journal of Clinical Oncology · 2
High dose Interleukin2 (HD IL2) in metastatic renal cell carcinoma (mRCC) after prior therapy: A single centre experience.
2018 · Shien Chow, Rebecca Leach, et al. · Journal of Clinical Oncology · 2
First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial
2014 · Manon Evans, Ryan Guest, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
2026 · Rebecca J. Lee, Dominic G. Rothwell, et al. · Nature Communications · 1
Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
2022 · Jonathan Heseltine, Jennifer Allison, et al. · Journal of Clinical Oncology · 1
High dose Interleukin 2 (HD IL2) as 1st line treatment in metastatic renal cell carcinoma (mRCC): A 10-year single centre experience.
2016 · Shien Chow, Victoria Galvis, et al. · Journal of Clinical Oncology · 1
Evaluating the Place of Interleukin-2 in the Management of Metastatic Renal Cell Cancer (MRCC) in the Era of Targeted Therapy
2014 · M. Evans, S. Chow, et al. · Annals of Oncology · 1
PDF
The unexpected challenges of immunotherapy
2018 · A.C. Olsson-Brown, T.J. Guinan, et al. · Annals of Oncology
Non-elective admissions in cancer care - A review of acute oncology services (AOS) implementation in a north-west region of England
2017 · S. Chow, R. Leach, et al. · Annals of Oncology
PDF
Adoptive Cell Therapy for metastatic melanoma: A UK centre experience.
2015 · Manon Rhys Pillai, Ryan Guest, et al. · Journal of Clinical Oncology
High-Dose Interleukin-2 (Hd Il2) Armed with Pathology-Based Selection Criteria: a Real Option in Treatment of Metastatic Renal Cell Carcinoma (Mrcc) After Targeted Therapy
2014 · S. Chow, V. Galvis, et al. · Annals of Oncology
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
2014 · Shien Chow, Manon Evans, et al. · Journal for ImmunoTherapy of Cancer
PDF
P044 Sequential everolimus in metastatic Renal Cell Carcinoma (mRCC): A single-institution experience in clinical practice
2013 · K. Chan, S. Chow, et al. · European Urology Supplements
Hospital Follow Up in Ovarian Cancer: Physical Examination Does Not Improve Relapse Detection or Survival
2012 · S. Chow, S. Ayers, et al. · Annals of Oncology
Works count: 25
Citation count: 123
H-index: 6
I10-index: 4
Year
Topic
Type